IMVT earnings date and last-quarter result: next report 2026-08-10, last quarter miss, P/E -14.05. Updated 2026-07-23.
Immunovant (IMVT) Research Hub
Immunovant (IMVT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 28.17 USD (-0.84%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.05, market cap 8.04B. This hub links to the full technical, earnings and options research available for IMVT.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 28.17 USD (-0.84%) |
| 52-week range | 26.26 USD – 45.42 USD |
| Trend regime | Range |
| 14-day RSI | 29.3 (Oversold) |
| Trailing P/E | -14.05 |
| Market cap | 8.04B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for IMVT
Covered Call on IMVT: how it works, illustrative setup around the real 28.17 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IMVT: how it works, illustrative setup around the real 28.17 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IMVT: how it works, illustrative setup around the real 28.17 USD price, max profit/loss, breakeven and when to use it. Educational.
IMVT technical analysis: range, last 28.17 USD, RSI 29.3, 52w range 26.26 USD–45.42 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is IMVT in?
Immunovant (IMVT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is IMVT in an uptrend or downtrend?
As of 2026-10-26, IMVT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IMVT's trailing P/E ratio?
IMVT's trailing P/E is -14.05, with a market cap of 8.04B. See the earnings research page for full valuation detail.
When does IMVT next report earnings?
IMVT is next scheduled to report earnings on 2026-08-10.